Loading...
XNAS
ACAD
Market cap4.54bUSD
Jul 09, Last price  
26.41USD
1D
1.58%
1Q
21.48%
Jan 2017
-8.43%
IPO
299.55%
Name

ACADIA Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:ACAD chart
P/E
11.57
P/S
4.22
EPS
2.28
Div Yield, %
—
Shrs. gr., 5y
1.72%
Rev. gr., 5y
19.39%
Revenues
1.07b
+11.87%
8,133,0007,555,0001,590,0006,399,00042,135,0002,067,0004,907,0001,145,000120,00061,00017,331,000124,901,000223,807,000339,076,000441,755,000484,145,000517,235,000726,437,000957,797,0001,071,505,000
Net income
391m
+72.66%
-45,048,000-56,390,000-64,244,000-45,145,00015,139,000-22,765,000-20,849,000-37,948,000-92,475,000-164,443,000-271,393,000-289,403,000-245,192,000-235,259,000-281,584,000-167,870,000-215,975,000-61,286,000226,451,000391,000,000
CFO
110m
-30.36%
-41,418,000-54,926,000-64,869,000-13,727,000-10,703,000-19,897,000-21,633,000-31,769,000-66,434,000-121,795,000-210,408,000-217,857,000-167,470,000-151,130,000-136,166,000-125,660,000-114,035,00016,702,000157,719,000109,836,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
URL
https://acadia.com/
IPO date
May 27, 2004
Employees
540
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT